CN Patent

CN116036031A — 一种含有瑞德西韦的药物组合物

Assigned to Qilu Pharmaceutical Co Ltd · Expires 2023-05-02 · 3y expired

What this patent protects

本发明名称为一种含有瑞德西韦的药物组合物。具体涉及一种以具有抗病毒活性的化合物瑞德西韦为活性成份的药物组合物，属于药物制剂技术领域。本发明制备的瑞德西韦药物组合物对于轻中度患者服用方便，增加了患者用药的顺应性，有较大的临床应用价值；此外，本发明制备的瑞德西韦药物组合物质量稳定、可控，便于工业化生产。

USPTO Abstract

本发明名称为一种含有瑞德西韦的药物组合物。具体涉及一种以具有抗病毒活性的化合物瑞德西韦为活性成份的药物组合物，属于药物制剂技术领域。本发明制备的瑞德西韦药物组合物对于轻中度患者服用方便，增加了患者用药的顺应性，有较大的临床应用价值；此外，本发明制备的瑞德西韦药物组合物质量稳定、可控，便于工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN116036031A
Jurisdiction
CN
Classification
—
Expires
2023-05-02
Drug substance claim
No
Drug product claim
No
Assignee
Qilu Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.